Ozempic (semaglutide) is the GLP-1 drug that put weekly incretin therapy on the map. Retatrutide is Eli Lilly's investigational GLP-1/GIP/glucagon triple agonist that in Phase 2 produced mean weight loss of roughly 24% at 48 weeks — about 10 percentage points more than semaglutide's STEP-1 result. Here is the straight head-to-head on mechanism, data, approval status, and the questions that only a direct trial can settle.
Key Takeaways
- Different receptor profiles. Semaglutide is a GLP-1 mono-agonist; retatrutide is a GLP-1/GIP/glucagon triple agonist.
- Semaglutide is approved, retatrutide is not. Ozempic (T2D) and Wegovy (obesity) are FDA-approved. Retatrutide is still in Phase 3 as of early 2026.
- Weight loss gap is large on paper. STEP-1 reported ~14.9% at 68 weeks for semaglutide 2.4 mg; retatrutide Phase 2 reported ~24% at 48 weeks at 12 mg.
- No direct head-to-head yet. Cross-trial comparison is directional only.
- Tirzepatide beat semaglutide head-to-head in SURMOUNT-5. 20.2% vs 13.7% at 72 weeks — relevant context for triple-agonist expectations.
- Approval timing is the key variable. Retatrutide approval is widely expected in 2026–2027 if the Phase 3 program reads out cleanly.
Mechanism — mono-agonist vs triple agonist
Semaglutide is a long-acting analogue of glucagon-like peptide-1 (GLP-1). It binds the GLP-1 receptor, which enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central pathways. One receptor, three main effects.
Retatrutide activates three receptors — GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. Adding GIP broadens the metabolic effect in ways similar to tirzepatide; adding glucagon receptor activity is the novel feature. Glucagon agonism increases energy expenditure and promotes hepatic fatty-acid oxidation. The hypothesis — supported by the Phase 2 data — is that these three signals combined deliver more weight loss than one or two.
Approval status and brand map
Semaglutide is marketed by Novo Nordisk under three brand names depending on dose and indication: Ozempic (T2D, up to 2.0 mg weekly), Wegovy (obesity, 2.4 mg weekly), and Rybelsus (oral T2D). Retatrutide has no brand name yet because it is not approved. Lilly's Phase 3 program (TRIUMPH-1 through -5) is designed to support regulatory filings for both obesity and type 2 diabetes.
Published weight-loss data side by side
| Metric | Semaglutide 2.4 mg (STEP-1) | Retatrutide 12 mg (Phase 2) |
|---|---|---|
| Mechanism | GLP-1 mono-agonist | GLP-1 / GIP / glucagon triple agonist |
| Dose and cadence | 2.4 mg once weekly | 12 mg once weekly |
| Trial duration | 68 weeks | 48 weeks |
| Mean weight loss | ~14.9% | ~24.0% |
| Participants ≥20% loss | ~32% | ~63% |
| Discontinuation (AEs) | ~7% | ~6–10% |
| Approval status | FDA-approved (as Wegovy) | Phase 3; not approved as of early 2026 |
| Approximate list price (US) | ~$1,300/mo (Wegovy) | Not yet priced |
These are not head-to-head trials. STEP-1 ran 68 weeks and recruited a different population; retatrutide Phase 2 ran 48 weeks. A fair comparison would need a direct trial — none has been published to date.
The SURMOUNT-5 context
The closest thing to a modern head-to-head between an incretin single agonist and a multi-agonist is SURMOUNT-5, which pitted tirzepatide (GLP-1/GIP dual agonist) against semaglutide. In that trial, tirzepatide delivered mean weight loss of 20.2% versus 13.7% for semaglutide at 72 weeks.
| Trial | Comparator | Weight loss | Duration | Design |
|---|---|---|---|---|
| SURMOUNT-5 | Tirzepatide vs semaglutide | 20.2% vs 13.7% | 72 weeks | Direct head-to-head |
| STEP-1 | Semaglutide vs placebo | 14.9% vs 2.4% | 68 weeks | Placebo-controlled |
| SURMOUNT-1 | Tirzepatide vs placebo | 20.9% vs 3.1% | 72 weeks | Placebo-controlled |
| Retatrutide Phase 2 | Retatrutide vs placebo | 24.0% vs 2.1% | 48 weeks | Placebo-controlled (Phase 2) |
What SURMOUNT-5 established is that moving from one incretin receptor to two produced a real head-to-head weight-loss gain. Whether moving from two receptors to three (adding glucagon) produces an equivalent step up is the implicit hypothesis of the retatrutide program — but the direct comparison between retatrutide and either semaglutide or tirzepatide has not been published.
Tolerability and side effects
Both drugs produce the familiar incretin side-effect profile: nausea, vomiting, diarrhea, constipation, decreased appetite — dose-dependent, mostly mild-to-moderate, concentrated during titration. Nausea rates at top dose are broadly comparable (~44% STEP-1 vs ~43% retatrutide Phase 2). Discontinuation rates for adverse events are in the same single-digit range. Semaglutide carries class warnings for thyroid C-cell tumors and pancreatitis monitoring; those warnings would likely carry over to any retatrutide label.
Cost and access
Semaglutide list price for Wegovy in the US runs roughly $1,300 per month before insurance negotiation or manufacturer coupons. Ozempic (same molecule, lower dose for T2D) is similar. Retatrutide pricing is unknown — Lilly has not published a figure because it is not yet an approved drug. Historically, novel incretin agents launch at parity-or-above pricing versus incumbents, so a retatrutide list price in a similar range would not surprise anyone.
Who each drug may be better for
As a research question, the segmentation is roughly:
- Semaglutide: already FDA-approved for both T2D and obesity, extensive long-term safety data, broad insurance coverage in some markets.
- Retatrutide: targets patients who need deeper weight loss than semaglutide delivers, assuming Phase 3 reads out clean. Not available clinically outside trials as of early 2026.
Nothing about this segmentation is a prescribing instruction — real choices should be made with a prescriber, with the final retatrutide label if and when it issues, and with trial data interpreted in individual context.
What the data do not tell us
Three gaps are worth naming. First, no direct head-to-head between retatrutide and semaglutide has been published. Second, retatrutide long-term safety past 72 weeks is still being characterized through Phase 3. Third, cardiovascular outcomes trials that drove semaglutide into major guideline recommendations have not yet been reported for retatrutide.
The glucagon receptor piece
What makes retatrutide mechanistically distinct from semaglutide and tirzepatide is the third receptor — glucagon. In most people's minds glucagon is "the thing that raises blood sugar," which sounds counterproductive for a diabetes-adjacent drug. The clinical bet behind retatrutide is more subtle. Glucagon receptor activation in the liver increases energy expenditure, promotes hepatic fat oxidation, and may push harder against hepatic steatosis. Paired with the strong insulin-secretory effect of GLP-1 and GIP agonism, the net glycemic effect in Phase 2 was favorable rather than destabilizing. Whether that balance holds across larger Phase 3 populations is one of the headline questions in the TRIUMPH program.
What a hypothetical direct trial would need to answer
If and when a direct head-to-head trial pits retatrutide against semaglutide, the questions it would need to answer are not just "which drug produces more weight loss" but also:
- Does the extra weight loss translate into better cardiovascular, renal, and metabolic outcomes, or is the delta cosmetic above a certain threshold?
- Does tolerability at matched weight-loss endpoints differ — i.e., for a given level of weight loss, which drug has fewer side effects?
- How does durability compare after discontinuation, which is where semaglutide has well-characterized rebound data?
None of these questions have published answers today. They are the research agenda that will shape prescribing choices once retatrutide (hopefully) issues.
Insurance, access, and the real-world picture
Even for semaglutide, which is approved, insurance coverage for weight-loss indications remains uneven. US commercial payers often cover Ozempic for T2D but gate Wegovy behind BMI and comorbidity requirements. A hypothetical retatrutide approval would likely face a similar landscape, with coverage expanding gradually as outcomes data accrue. From a research-reader standpoint, the implication is that trial efficacy numbers do not directly translate into clinical access.
Switching between agents
Patients already on semaglutide who might want to switch to a future retatrutide product face a question that currently has no published answer: how to transition. Both drugs are once-weekly subcutaneous incretin agonists, so biologically there is no major accumulation concern between a last semaglutide dose and a first retatrutide dose. The practical questions — whether to start retatrutide at the standard 0.5 mg titration, or at a higher dose scaled to the equivalent semaglutide maintenance, or to pause for a wash-out — will be answered by the eventual label. Until then, assume the trial-protocol starting dose applies.
Signals to watch next
Three near-term readouts will shape the retatrutide-vs-semaglutide picture more than any other data points. First, the TRIUMPH-1 primary endpoint report at 72 weeks, which locks in a direct Phase 3 efficacy and safety number. Second, any announced head-to-head trial between retatrutide and a comparator — none currently published. Third, the TRIUMPH-4 type 2 diabetes readout, which answers whether the triple-agonist advantage extends to glycemic control at the same magnitude it extends to weight loss. Each of those will tighten the comparison; none of them is on the public record yet.
Conclusion
On published numbers, retatrutide looks more powerful than semaglutide for weight loss by roughly 10 percentage points in cross-trial comparison. The weight-loss gap is real and large, but it is cross-trial and not confirmed by a direct head-to-head. Semaglutide has the structural advantage of being FDA-approved today with years of real-world safety data; retatrutide has the hypothetical advantage of adding glucagon receptor activity to the incretin playbook. Approval timing — likely 2026–2027 if Phase 3 reads out cleanly — is the single biggest variable to watch.
For now, Ozempic is a shipping drug and retatrutide is a research compound. That distinction matters as much as any efficacy number.
Frequently Asked Questions
Is retatrutide better than Ozempic?
On published Phase 2 weight-loss numbers, retatrutide produced roughly 10 percentage points more mean weight loss than semaglutide in STEP-1. But those are different trials — a direct head-to-head has not yet been published, and retatrutide is not yet FDA-approved.
What is the difference between Ozempic and retatrutide mechanistically?
Ozempic is semaglutide, a GLP-1 mono-agonist. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors.
When will retatrutide be FDA-approved?
Approval timing depends on completion and reporting of the TRIUMPH Phase 3 program. Industry expectations as of early 2026 cluster around 2026–2027 if Phase 3 reads out cleanly, but regulatory timelines are inherently uncertain.
How much weight do people lose on retatrutide vs Ozempic?
In Phase 2 at 48 weeks, retatrutide 12 mg produced ~24% mean weight loss. In STEP-1 at 68 weeks, semaglutide 2.4 mg produced ~14.9% mean weight loss. Different trials, different durations.
Can I take Ozempic and retatrutide together?
No. Both are long-acting incretin agonists, and stacking them is not studied, not recommended, and would compound side effects. Retatrutide is also not clinically available outside trials.
How much does retatrutide cost?
Retatrutide has no FDA-approved list price because it is not yet approved. Semaglutide (Wegovy) runs roughly $1,300 per month before insurance in the US as of early 2026.
Is retatrutide the same as tirzepatide?
No. Tirzepatide is a dual GLP-1/GIP agonist (Lilly's Mounjaro and Zepbound). Retatrutide adds a third receptor target, glucagon.
Primary sources:
- Jastreboff AM et al. Retatrutide Phase 2. NEJM 2023.
- Wilding JPH et al. STEP-1: Semaglutide 2.4 mg Once Weekly in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. SURMOUNT-1: Tirzepatide in Obesity. NEJM 2022.
- ClinicalTrials.gov: TRIUMPH-1
- Eli Lilly investor news releases
Research disclaimer: Retatrutide is an investigational compound not FDA-approved at the time of writing. Semaglutide (Ozempic, Wegovy, Rybelsus) is FDA-approved for specific indications; off-label use carries additional risks. This article is a research comparison for educational use only, not medical advice, and does not establish a doctor-patient relationship.
